Loading…
Loading…
EMMLF (OKYO Pharma Limited) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
EMMLF does not currently pay a dividend.
See exactly how EMMLF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EMMLF and 80,000+ other tickers.
OKYO Pharma Limited is an early-stage biopharmaceutical company focused on developing therapies for individuals experiencing inflammatory eye conditions and ocular pain. A key asset in their pipeline is OK-101, specifically aimed at treating dry eye disease. Additionally, the company is advancing OK-201, which is a preclinical lipidated-peptide analogue sourced from bovine adrenal medulla, intended for the management of neuropathic ocular pain. Founded in 2007, OKYO Pharma Limited is headquartered in London, United Kingdom.
OKYO Pharma (NASDAQ: OKYO ) stock is falling on Tuesday even after the biopharmaceutical company withdrew a public offering. According to a press release from the company, it decided to withdraw this offering after evaluating changing market conditions while seeking the best interest of its investors.
OKYO Pharma Ltd (NASDAQ:OKYO) has revealed a new partnership with Tufts Medical Center to conduct an open-label clinical trial to assess the efficacy and safety of OK-101 in treating patients with neuropathic corneal pain (NCP). NCP is a distressing condition that causes chronic and severe eye discomfort, severely impacting the quality of life for those affected.
OKYO Pharma said patients are being dosed in a randomise portion of a phase 2 trial for its OK-101 drug to treat dry eye disease (DED). The ophthalmology-focused biopharmaceutical company said in a statement that patients are being dosed in the phase 2 trial following a two-week placebo run-in period, which is designed to minimise the placebo effect.
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO), an ophthalmology-focused biopharmaceutical company, will showcase two presentations on its dry eye disease (DED) treatment, OK-101, at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, California, from May 5-8. Dr Pedram Hamrah, a leading expert on corneal neuropathic pain and DED, will present both papers at the conference.
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said the first patient had been screened for the phase II trial of OK-101, a treatment for dry eye disease (DED). It aims to evaluate the drug's efficacy and safety in DED patients.